Education
About Us
Working with TipRanks
Follow Us
AstraZeneca plc (AZNCF)
:AZNCF
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
2.2Last Year’s EPS
2.68Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: 3.24%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
The earnings call presented a largely positive outlook for AstraZeneca in 2025, with strong revenue growth, successful pipeline advancements, and strategic business developments. However, challenges such as product-specific declines and market-specific headwinds were acknowledged.Company Guidance
During AstraZeneca's Q1 2025 results conference call, key financial metrics highlighted included a 10% increase in total revenue, a 12% rise in core operating profit, and a 21% increase in core EPS, with the latter benefiting from a lower tax rate due to settlements. The company secured 13 approvals in key regions and announced five positive Phase III results, including camizestrant and eneboparatide. Revenue growth was driven by strong performances across therapy areas and geographies, with ex-China revenues in emerging markets up 17% and China revenues rising 5%. AstraZeneca reiterated its full-year guidance, anticipating high single-digit percentage total revenue growth and low double-digit percentage core EPS growth at constant exchange rates, with a low single-digit adverse impact from foreign exchange. The company's cash inflow from operating activities increased to $3.7 billion, and it continues to invest in manufacturing capabilities, maintaining a strong global footprint with 31 manufacturing sites.Strong Start to 2025
Total revenue growth was 10% in Q1, with core operating profit increasing by 12%, and core EPS increasing by 21%. The company secured 13 approvals across key regions and reported five positive Phase III results.
Oncology Business Growth
Oncology total revenues grew 13% to $5.6 billion, driven by strong double-digit growth across the U.S., Europe, and emerging markets. Key medicines like Tagrisso and Calquence saw significant volume growth.
Emerging Markets Performance
Ex-China revenues increased by 17%, and growth in China was 5%, driven by innovative medicines and new product launches.
Pipeline and Business Development
Several business development transactions were announced, including the acquisition of EsoBiotec and an investment in a new R&D center in Beijing, China.
Biopharmaceuticals Performance
Biopharmaceuticals revenue reached $5.6 billion, reflecting a growth of 12%. Farxiga revenues exceeded $2 billion for the first time.
AZNCF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AZNCF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $138.76 | $144.94 | +4.45% |
Feb 06, 2025 | $132.69 | $149.28 | +12.50% |
Nov 12, 2024 | $124.94 | $126.53 | +1.27% |
Jul 25, 2024 | $153.99 | $152.25 | -1.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AstraZeneca plc (AZNCF) report earnings?
AstraZeneca plc (AZNCF) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is AstraZeneca plc (AZNCF) earnings time?
AstraZeneca plc (AZNCF) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AZNCF EPS forecast?
AZNCF EPS forecast for the fiscal quarter 2025 (Q2) is 2.2.